董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Gannon | 男 | Director | 63 | 5.46万美元 | 未持股 | 2025-10-15 |
| Dawn Svoronos | 女 | Chair and Lead Independent Director | 71 | 5.07万美元 | 未持股 | 2025-10-15 |
| Patrick Machado | 男 | Director | 61 | 未披露 | 未持股 | 2025-10-15 |
| Gillian Cannon | 女 | Director | 61 | 未披露 | 未持股 | 2025-10-15 |
| Elizabeth Garofalo | 女 | Director | 67 | 未披露 | 未持股 | 2025-10-15 |
| Gary Patou | 男 | Director | 66 | 5.96万美元 | 未持股 | 2025-10-15 |
| Justin Gover | 男 | Director | 54 | 未披露 | 未持股 | 2025-10-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Kenney | 女 | Chief Medical Officer | 54 | 未披露 | 未持股 | 2025-10-15 |
| Andrea DiFabio | 女 | Chief Legal Officer and Corporate Secretary | 56 | 未披露 | 未持股 | 2025-10-15 |
| Thomas Kelly | 男 | Chief Financial Officer and Principal Accounting Officer | 54 | 未披露 | 未持股 | 2025-10-15 |
| Ian C. Mortimer | 男 | President,Chief Executive Officer and Principal Operating Officer | 49 | 94.48万美元 | 未持股 | 2025-10-15 |
董事简历
中英对照 | 中文 | 英文- Steven Gannon
-
Steven Gannon，曾担任Xenon Pharmaceuticals Inc.的成员。自2015年5月起担任董事会成员。Gannon先生自2021年4月起担任私人CRO/CDMO公司Altasciences的董事会主席；自2022年3月起担任Ritedose Pharmaceuticals的董事会成员；2016年9月起担任Laborie Technologies董事会成员。从2020年1月到2024年6月，他还担任Fusion Pharmaceuticals（一家公共生物制药公司）的董事会成员；从2017年2月到2023年6月担任生物技术公司enGene Inc.的董事会成员；从2018年11月到2020年7月，他是Aerogen Limited（一家医疗技术公司）的董事会成员。2014年6月至2018年3月，甘农先生担任Advanced Accelerator Applications SA（一家医疗保健公司，于2018年1月被诺华收购）的董事会成员。他曾担任Aptalis Pharma Inc.的首席财务官、财务高级副总裁兼财务主管，直到2014年2月，之后该公司被出售给Forest Laboratories。在2006年加入Aptalis之前，Gannon先生从1999年到2006年担任Cryocath Technologies Inc.的首席财务官，从1996年到1999年担任AstraZeneca Canada Inc.研究部门的财务和行政总监，从1989年到1995年担任Mallinckrodt Medical Inc.加拿大业务的首席财务官。他于1983年在加拿大蒙特利尔的Concordia大学获得会计和商业系统学士学位，并于1995年在加拿大安大略省的西安大略大学的Richard Ivey商学院完成了高管课程。自1985年以来，他一直是注册会计师。
Steven Gannon,has served as a member of Xenon Pharmaceuticals Inc. Board since May 2015. Mr. Gannon has served as chairman of the board of directors of Altasciences, a private CRO/CDMO company, since April 2021; on the board of directors of Ritedose Pharmaceuticals since March 2022; and on the board of directors of Laborie Technologies since September 2016. Mr. Gannon also served on the board of directors of Fusion Pharmaceuticals, a public biopharmaceutical company, from January 2020 to June 2024; on the board of directors of enGene Inc., a biotechnology company, from February 2017 to June 2023; and on the board of directors of Aerogen Limited, a medical technology company, from November 2018 to July 2020. From June 2014 to March 2018, Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014, after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006, Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006, as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999, and as the Chief Financial Officer of Mallinckrodt Medical Inc.'s Canadian operations from 1989 to 1995. He received a bachelor of commerce in accounting and business systems from Concordia University in Montreal, Canada in 1983, and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a CPA, CA since 1985. - Steven Gannon，曾担任Xenon Pharmaceuticals Inc.的成员。自2015年5月起担任董事会成员。Gannon先生自2021年4月起担任私人CRO/CDMO公司Altasciences的董事会主席；自2022年3月起担任Ritedose Pharmaceuticals的董事会成员；2016年9月起担任Laborie Technologies董事会成员。从2020年1月到2024年6月，他还担任Fusion Pharmaceuticals（一家公共生物制药公司）的董事会成员；从2017年2月到2023年6月担任生物技术公司enGene Inc.的董事会成员；从2018年11月到2020年7月，他是Aerogen Limited（一家医疗技术公司）的董事会成员。2014年6月至2018年3月，甘农先生担任Advanced Accelerator Applications SA（一家医疗保健公司，于2018年1月被诺华收购）的董事会成员。他曾担任Aptalis Pharma Inc.的首席财务官、财务高级副总裁兼财务主管，直到2014年2月，之后该公司被出售给Forest Laboratories。在2006年加入Aptalis之前，Gannon先生从1999年到2006年担任Cryocath Technologies Inc.的首席财务官，从1996年到1999年担任AstraZeneca Canada Inc.研究部门的财务和行政总监，从1989年到1995年担任Mallinckrodt Medical Inc.加拿大业务的首席财务官。他于1983年在加拿大蒙特利尔的Concordia大学获得会计和商业系统学士学位，并于1995年在加拿大安大略省的西安大略大学的Richard Ivey商学院完成了高管课程。自1985年以来，他一直是注册会计师。
- Steven Gannon,has served as a member of Xenon Pharmaceuticals Inc. Board since May 2015. Mr. Gannon has served as chairman of the board of directors of Altasciences, a private CRO/CDMO company, since April 2021; on the board of directors of Ritedose Pharmaceuticals since March 2022; and on the board of directors of Laborie Technologies since September 2016. Mr. Gannon also served on the board of directors of Fusion Pharmaceuticals, a public biopharmaceutical company, from January 2020 to June 2024; on the board of directors of enGene Inc., a biotechnology company, from February 2017 to June 2023; and on the board of directors of Aerogen Limited, a medical technology company, from November 2018 to July 2020. From June 2014 to March 2018, Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014, after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006, Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006, as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999, and as the Chief Financial Officer of Mallinckrodt Medical Inc.'s Canadian operations from 1989 to 1995. He received a bachelor of commerce in accounting and business systems from Concordia University in Montreal, Canada in 1983, and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a CPA, CA since 1985.
- Dawn Svoronos
-
Dawn Svoronos，自2021年6月起担任Xenon Pharmaceuticals Inc.首席独立董事后，自2024年6月起担任Xenon Pharmaceuticals Inc.董事会主席，并自2016年9月起担任TERM3董事会成员。Svoronos女士是以下上市生物制药公司的董事会成员：Acelyrin Inc.、Adverum生物科技，Inc.和Theratechnologies Inc.。Svoronos女士于2011年从默沙东 & Co.，Inc.退休，此前她在越来越年长的商业职位上工作了23年，最近担任的是欧洲和加拿大总裁。她此前曾在默沙东担任过职务，包括关节炎、镇痛药和骨质疏松症专营权的亚太区副总裁和全球营销副总裁。Svoronos女士此前曾在PTC Therapeutics，Inc.、全球血液疗法公司、Endocyte, Inc.和Medivation Inc.的董事会任职。Svoronos女士曾获得卡尔顿大学的英语和法语文学学士学位。
Dawn Svoronos,has served as the Chair of Xenon Pharmaceuticals Inc. Board since June 2024 after serving as Xenon Pharmaceuticals Inc. Lead Independent Director since June 2021, and has served as a member of Xenon Pharmaceuticals Inc. Board since September 2016. Ms. Svoronos sits on the boards of directors of the following publicly traded biopharmaceutical companies: Acelyrin Inc., Adverum Biotechnologies, Inc. and Theratechnologies Inc. Ms. Svoronos retired in 2011 from Merck & Co., Inc. following a 23-year career in commercial positions of increasing seniority, most recently as President of Europe and Canada. Her previously held positions with Merck include Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos previously sat on the boards of PTC Therapeutics, Inc., Global Blood Therapeutics, Inc., Endocyte, Inc., and Medivation Inc. Ms. Svoronos received a B.A. in English and French Literature from Carleton University. - Dawn Svoronos，自2021年6月起担任Xenon Pharmaceuticals Inc.首席独立董事后，自2024年6月起担任Xenon Pharmaceuticals Inc.董事会主席，并自2016年9月起担任TERM3董事会成员。Svoronos女士是以下上市生物制药公司的董事会成员：Acelyrin Inc.、Adverum生物科技，Inc.和Theratechnologies Inc.。Svoronos女士于2011年从默沙东 & Co.，Inc.退休，此前她在越来越年长的商业职位上工作了23年，最近担任的是欧洲和加拿大总裁。她此前曾在默沙东担任过职务，包括关节炎、镇痛药和骨质疏松症专营权的亚太区副总裁和全球营销副总裁。Svoronos女士此前曾在PTC Therapeutics，Inc.、全球血液疗法公司、Endocyte, Inc.和Medivation Inc.的董事会任职。Svoronos女士曾获得卡尔顿大学的英语和法语文学学士学位。
- Dawn Svoronos,has served as the Chair of Xenon Pharmaceuticals Inc. Board since June 2024 after serving as Xenon Pharmaceuticals Inc. Lead Independent Director since June 2021, and has served as a member of Xenon Pharmaceuticals Inc. Board since September 2016. Ms. Svoronos sits on the boards of directors of the following publicly traded biopharmaceutical companies: Acelyrin Inc., Adverum Biotechnologies, Inc. and Theratechnologies Inc. Ms. Svoronos retired in 2011 from Merck & Co., Inc. following a 23-year career in commercial positions of increasing seniority, most recently as President of Europe and Canada. Her previously held positions with Merck include Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos previously sat on the boards of PTC Therapeutics, Inc., Global Blood Therapeutics, Inc., Endocyte, Inc., and Medivation Inc. Ms. Svoronos received a B.A. in English and French Literature from Carleton University.
- Patrick Machado
-
Patrick Machado，自2021年4月起担任Acelyrin公司董事会成员。Machado先生是生物制药公司Medivation, Inc.的联合创始人，2009年12月至2014年4月担任公司首席商务官，2004年12月至2014年3月担任公司首席财务官。1998年至2001年，Machado先生在医疗设备公司ProDuct Health，Inc.工作，担任高级副总裁、首席财务官，并在此之前担任总法律顾问。在ProDuct Health Inc.被诊断和医疗设备公司Cytyc Corporation收购后，他在2001年至2002年期间担任Cytyc Corporation的顾问，协助处理过渡事项。在其职业生涯的早期，马查多曾为国际律师事务所Morrison & Foerster LLP和马萨诸塞州最高法院工作。Machado先生还自2017年3月起担任上市公司Adverum Biotechnologies, Inc.董事会主席，自2019年12月起担任上市公司Arcus Biosciences, Inc.董事会成员，自2014年6月起担任上市公司Chimerix, Inc.，自2020年11月起担任上市公司Xenon制药，自2018年8月起担任Turnstone Biologics Inc.董事会成员。Machado先生曾于2019年5月至2022年9月担任上市公司的董事会成员，如Turning Point医疗公司，2018年2月至2018年12月担任Endocyte公司，2017年6月至2018年2月担任Axovant Sciences公司，2015年9月至2019年6月担任SCYNEXIS公司，2014年4月至2016年9月担任Medivation公司，2016年8月至2018年1月担任Inotek Pharmaceuticals Corporation（现为Rocket制药公司），2019年6月至2020年9月担任Principia Biopharma公司董事会成员，从2016年10月至2022年6月，以及从2019年1月至2019年7月的Therachon AG。他在哈佛大学法学院获得法学博士学位，在圣克拉拉大学获得德语学士学位和经济学学士学位。
Patrick Machado,has served as a member of Acelyrin, Inc board of directors since April 2021. Mr. Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from December 2009 to April 2014 and as its chief financial officer from December 2004 until his retirement in March 2014. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health Inc.'s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc Corporation to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as chair of the board of directors of Adverum Biotechnologies, Inc., a publicly traded company, since March 2017 and as a member of the board of directors of Arcus Biosciences, Inc., a publicly traded company, since December 2019, Chimerix, Inc., a publicly traded company, since June 2014, Xenon Pharmaceuticals, Inc., a publicly traded company, since November 2020, and Turnstone Biologics Inc. since August 2018. Mr. Machado previously served on the board of directors of public traded companies such as Turning Point Therapeutics, Inc. from May 2019 to September 2022, Endocyte, Inc. from February 2018 to December 2018, Axovant Sciences, Inc. from June 2017 to February 2018, SCYNEXIS, Inc. from September 2015 to June 2019, Medivation, Inc. from April 2014 to September 2016; Inotek Pharmaceuticals Corporation (now Rocket Pharmaceuticals, Inc.) from August 2016 to January 2018 and Principia Biopharma Inc. from June 2019 to September 2020; and on the board of directors of privately held companies such as Roivant Sciences, Ltd. from October 2016 to June 2022, and Therachon AG from January 2019 to July 2019. He received a J.D. from Harvard Law School and a B.A. in German and a B.S. in Economics from Santa Clara University. - Patrick Machado，自2021年4月起担任Acelyrin公司董事会成员。Machado先生是生物制药公司Medivation, Inc.的联合创始人，2009年12月至2014年4月担任公司首席商务官，2004年12月至2014年3月担任公司首席财务官。1998年至2001年，Machado先生在医疗设备公司ProDuct Health，Inc.工作，担任高级副总裁、首席财务官，并在此之前担任总法律顾问。在ProDuct Health Inc.被诊断和医疗设备公司Cytyc Corporation收购后，他在2001年至2002年期间担任Cytyc Corporation的顾问，协助处理过渡事项。在其职业生涯的早期，马查多曾为国际律师事务所Morrison & Foerster LLP和马萨诸塞州最高法院工作。Machado先生还自2017年3月起担任上市公司Adverum Biotechnologies, Inc.董事会主席，自2019年12月起担任上市公司Arcus Biosciences, Inc.董事会成员，自2014年6月起担任上市公司Chimerix, Inc.，自2020年11月起担任上市公司Xenon制药，自2018年8月起担任Turnstone Biologics Inc.董事会成员。Machado先生曾于2019年5月至2022年9月担任上市公司的董事会成员，如Turning Point医疗公司，2018年2月至2018年12月担任Endocyte公司，2017年6月至2018年2月担任Axovant Sciences公司，2015年9月至2019年6月担任SCYNEXIS公司，2014年4月至2016年9月担任Medivation公司，2016年8月至2018年1月担任Inotek Pharmaceuticals Corporation（现为Rocket制药公司），2019年6月至2020年9月担任Principia Biopharma公司董事会成员，从2016年10月至2022年6月，以及从2019年1月至2019年7月的Therachon AG。他在哈佛大学法学院获得法学博士学位，在圣克拉拉大学获得德语学士学位和经济学学士学位。
- Patrick Machado,has served as a member of Acelyrin, Inc board of directors since April 2021. Mr. Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from December 2009 to April 2014 and as its chief financial officer from December 2004 until his retirement in March 2014. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health Inc.'s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc Corporation to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as chair of the board of directors of Adverum Biotechnologies, Inc., a publicly traded company, since March 2017 and as a member of the board of directors of Arcus Biosciences, Inc., a publicly traded company, since December 2019, Chimerix, Inc., a publicly traded company, since June 2014, Xenon Pharmaceuticals, Inc., a publicly traded company, since November 2020, and Turnstone Biologics Inc. since August 2018. Mr. Machado previously served on the board of directors of public traded companies such as Turning Point Therapeutics, Inc. from May 2019 to September 2022, Endocyte, Inc. from February 2018 to December 2018, Axovant Sciences, Inc. from June 2017 to February 2018, SCYNEXIS, Inc. from September 2015 to June 2019, Medivation, Inc. from April 2014 to September 2016; Inotek Pharmaceuticals Corporation (now Rocket Pharmaceuticals, Inc.) from August 2016 to January 2018 and Principia Biopharma Inc. from June 2019 to September 2020; and on the board of directors of privately held companies such as Roivant Sciences, Ltd. from October 2016 to June 2022, and Therachon AG from January 2019 to July 2019. He received a J.D. from Harvard Law School and a B.A. in German and a B.S. in Economics from Santa Clara University.
- Gillian Cannon
-
Gillian Cannon，自2023年8月起担任Xenon Pharmaceuticals Inc.董事会成员。Cannon博士带来了30多年的制药行业经验，她曾在多家知名全球制药公司担任领导职务，包括默沙东和株式会社、UCB Inc.和大冢制药。Cannon博士在默沙东服务超过25年，曾担任多个高级职位，包括默沙东初创的生物类似物业务默沙东 BioVentures的商业运营全球副总裁；默沙东特种产品特许经营的业务部门负责人，以及默沙东神经科学特许经营的全球商业负责人。最近，坎农博士担任美国总统。
Gillian Cannon,has served as a member of Xenon Pharmaceuticals Inc. Board since August 2023. Dr. Cannon has more than 30 years of experience in the pharmaceutical industry, where she has served in leadership roles at multiple prominent global pharmaceutical companies including Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. Serving more than 25 years at Merck, Dr. Cannon held a variety of senior positions, including Global Vice President for Commercial Operations at Merck's start-up biosimilar business, Merck BioVentures; Business Unit Head for Merck's specialty products franchise, and Global Commercial Head of Merck's neuroscience franchise. More recently, Dr. Cannon was the President of U.S. - Gillian Cannon，自2023年8月起担任Xenon Pharmaceuticals Inc.董事会成员。Cannon博士带来了30多年的制药行业经验，她曾在多家知名全球制药公司担任领导职务，包括默沙东和株式会社、UCB Inc.和大冢制药。Cannon博士在默沙东服务超过25年，曾担任多个高级职位，包括默沙东初创的生物类似物业务默沙东 BioVentures的商业运营全球副总裁；默沙东特种产品特许经营的业务部门负责人，以及默沙东神经科学特许经营的全球商业负责人。最近，坎农博士担任美国总统。
- Gillian Cannon,has served as a member of Xenon Pharmaceuticals Inc. Board since August 2023. Dr. Cannon has more than 30 years of experience in the pharmaceutical industry, where she has served in leadership roles at multiple prominent global pharmaceutical companies including Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. Serving more than 25 years at Merck, Dr. Cannon held a variety of senior positions, including Global Vice President for Commercial Operations at Merck's start-up biosimilar business, Merck BioVentures; Business Unit Head for Merck's specialty products franchise, and Global Commercial Head of Merck's neuroscience franchise. More recently, Dr. Cannon was the President of U.S.
- Elizabeth Garofalo
-
Elizabeth Garofalo，自2021年6月起担任Xenon Pharmaceuticals Inc.董事会成员。自2016年以来，Garofalo博士一直担任EAG Pharma Consulting LLC的负责人。在此之前，她担任过多个领导职务，包括担任诺华高级副总裁兼临床开发全球负责人以及全球开发领导团队成员；诺华产品组合管理委员会主席；诺华神经科学特许经营权联席负责人；安斯泰来神经科学治疗领域负责人；辉瑞安娜堡站点全球监管事务负责人；辉瑞安娜堡站点神经科学负责人。自2020年9月以来，Garofalo博士一直担任Acadia Pharmaceuticals Inc.的董事会成员，并于2024年12月成为薪酬委员会成员；自2021年9月起，作为Alector, Inc.的董事，她担任审计委员会成员和薪酬委员会主席。2021年3月，她加入了生物技术公司Exicure公司的董事会，并于2022年2月被任命为该公司董事会主席以及审计和薪酬委员会成员。她于2023年2月从Exicure董事会辞职。她是非营利性儿童高级临床试验研究所（I-ACT）的董事，她是该研究所的董事会主席。几年来，她一直担任美国癫痫基金会商业顾问委员会主席。她拥有印第安纳大学医学院的医学博士学位，并在密歇根大学医学院完成了小儿神经病学和癫痫研究金。
Elizabeth Garofalo,has served as a member of Xenon Pharmaceuticals Inc. Board since June 2021. Since 2016, Dr. Garofalo has served as the principal for EAG Pharma Consulting LLC. Previously, she served in numerous leadership roles including as Senior Vice President and Global Head of Clinical Development for Novartis and as a member of its Global Development Leadership Team; Chair of the Novartis Portfolio Stewardship Board; Co-Head of the Novartis Neuroscience Franchise; Head of the Neuroscience Therapy Area at Astellas; Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer; and Ann Arbor Site Head of Neuroscience at Pfizer. Since September 2020, Dr. Garofalo has served on the board of directors of Acadia Pharmaceuticals Inc., where she became a member of the compensation committee in December 2024, and, since September 2021, as a director of Alector, Inc., where she was a member of the audit committee and is chair of the compensation committee. In March 2021 she joined the board of directors of Exicure Inc., a biotechnology company, and in February 2022 was named the chair of its board of directors and a member of its audit and compensation committees. She resigned from the Exicure board in February 2023. She is a director of the non-profit Institute for Advanced Clinical Trials for Children (I-ACT) where she is chair of the board of directors. For several years, she was the chair of the Business Advisory Board for the Epilepsy Foundation of America. She has an M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School. - Elizabeth Garofalo，自2021年6月起担任Xenon Pharmaceuticals Inc.董事会成员。自2016年以来，Garofalo博士一直担任EAG Pharma Consulting LLC的负责人。在此之前，她担任过多个领导职务，包括担任诺华高级副总裁兼临床开发全球负责人以及全球开发领导团队成员；诺华产品组合管理委员会主席；诺华神经科学特许经营权联席负责人；安斯泰来神经科学治疗领域负责人；辉瑞安娜堡站点全球监管事务负责人；辉瑞安娜堡站点神经科学负责人。自2020年9月以来，Garofalo博士一直担任Acadia Pharmaceuticals Inc.的董事会成员，并于2024年12月成为薪酬委员会成员；自2021年9月起，作为Alector, Inc.的董事，她担任审计委员会成员和薪酬委员会主席。2021年3月，她加入了生物技术公司Exicure公司的董事会，并于2022年2月被任命为该公司董事会主席以及审计和薪酬委员会成员。她于2023年2月从Exicure董事会辞职。她是非营利性儿童高级临床试验研究所（I-ACT）的董事，她是该研究所的董事会主席。几年来，她一直担任美国癫痫基金会商业顾问委员会主席。她拥有印第安纳大学医学院的医学博士学位，并在密歇根大学医学院完成了小儿神经病学和癫痫研究金。
- Elizabeth Garofalo,has served as a member of Xenon Pharmaceuticals Inc. Board since June 2021. Since 2016, Dr. Garofalo has served as the principal for EAG Pharma Consulting LLC. Previously, she served in numerous leadership roles including as Senior Vice President and Global Head of Clinical Development for Novartis and as a member of its Global Development Leadership Team; Chair of the Novartis Portfolio Stewardship Board; Co-Head of the Novartis Neuroscience Franchise; Head of the Neuroscience Therapy Area at Astellas; Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer; and Ann Arbor Site Head of Neuroscience at Pfizer. Since September 2020, Dr. Garofalo has served on the board of directors of Acadia Pharmaceuticals Inc., where she became a member of the compensation committee in December 2024, and, since September 2021, as a director of Alector, Inc., where she was a member of the audit committee and is chair of the compensation committee. In March 2021 she joined the board of directors of Exicure Inc., a biotechnology company, and in February 2022 was named the chair of its board of directors and a member of its audit and compensation committees. She resigned from the Exicure board in February 2023. She is a director of the non-profit Institute for Advanced Clinical Trials for Children (I-ACT) where she is chair of the board of directors. For several years, she was the chair of the Business Advisory Board for the Epilepsy Foundation of America. She has an M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School.
- Gary Patou
-
Gary Patou，自2004年1月起担任Xenon Pharmaceuticals Inc.董事会成员。Patou博士自2020年8月起担任Star Therapeutics Inc.的首席医疗官。Patou博士自2019年1月起担任临床前阶段生物制药公司BioIntervene Inc.的董事会成员和首席医疗官。此前，Patou博士曾于2005年至2020年担任MPM Capital的执行合伙人，并曾在多家MPM投资组合公司担任临时首席医疗官，包括2018年10月至2020年12月在Blade Therapeutics任职。在加入MPM之前，Patou博士在Oscient Pharmaceuticals Corp.与GeneSoft Pharmaceuticals，Inc.合并后的2004年2月至2005年4月期间担任执行副总裁兼首席医疗官。在加入GeneSoft之前，Patou博士曾在SmithKline BeeCham Pharmaceuticals（现为葛兰素史克的一个部门）工作，担任高级副总裁兼项目和投资组合管理总监，管理公司的所有药物开发项目。Patou博士曾在University College & Middlesex School of Medicine担任过多个学术职务，并获得了伦敦大学的理学学士学位和伦敦大学学院的医学博士学位。
Gary Patou,has served as a member of Xenon Pharmaceuticals Inc. Board since January 2004. Dr. Patou has served as a Chief Medical Officer at Star Therapeutics Inc. since August 2020. Dr. Patou has served as a member of the board of directors and Chief Medical Officer for BioIntervene Inc., a preclinical stage biopharmaceutical company, since January 2019. Previously, Dr. Patou was an Executive Partner at MPM Capital from 2005 until 2020, and has served as interim Chief Medical Officer in various MPM portfolio companies, including at Blade Therapeutics from October 2018 to December 2020. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 following its merger with GeneSoft Pharmaceuticals, Inc. Prior to GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company's pharmaceutical development projects. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London. - Gary Patou，自2004年1月起担任Xenon Pharmaceuticals Inc.董事会成员。Patou博士自2020年8月起担任Star Therapeutics Inc.的首席医疗官。Patou博士自2019年1月起担任临床前阶段生物制药公司BioIntervene Inc.的董事会成员和首席医疗官。此前，Patou博士曾于2005年至2020年担任MPM Capital的执行合伙人，并曾在多家MPM投资组合公司担任临时首席医疗官，包括2018年10月至2020年12月在Blade Therapeutics任职。在加入MPM之前，Patou博士在Oscient Pharmaceuticals Corp.与GeneSoft Pharmaceuticals，Inc.合并后的2004年2月至2005年4月期间担任执行副总裁兼首席医疗官。在加入GeneSoft之前，Patou博士曾在SmithKline BeeCham Pharmaceuticals（现为葛兰素史克的一个部门）工作，担任高级副总裁兼项目和投资组合管理总监，管理公司的所有药物开发项目。Patou博士曾在University College & Middlesex School of Medicine担任过多个学术职务，并获得了伦敦大学的理学学士学位和伦敦大学学院的医学博士学位。
- Gary Patou,has served as a member of Xenon Pharmaceuticals Inc. Board since January 2004. Dr. Patou has served as a Chief Medical Officer at Star Therapeutics Inc. since August 2020. Dr. Patou has served as a member of the board of directors and Chief Medical Officer for BioIntervene Inc., a preclinical stage biopharmaceutical company, since January 2019. Previously, Dr. Patou was an Executive Partner at MPM Capital from 2005 until 2020, and has served as interim Chief Medical Officer in various MPM portfolio companies, including at Blade Therapeutics from October 2018 to December 2020. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 following its merger with GeneSoft Pharmaceuticals, Inc. Prior to GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company's pharmaceutical development projects. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London.
- Justin Gover
-
1999年1月以来，Justin Gover担任首席执行官。他拥有17年制药行业的经验。作为一名首席执行官，他负责业务运行以及领先的股本融资和商业开发活动。从1995年到1997年，他担任道德控股有限公司负责人，他负责战略活动，包括并购、战略投资、股权融资和投资者关系。他拥有欧洲工商管理学院硕士学位和布里斯托尔大学的理学学士学位。
Justin Gover has served as Chief Executive Officer of the Company since January 1999 shortly after the Company was founded.As Chief Executive Officer, Mr. Gover has been the lead executive responsible for running the Company's operations, as well as leading equity financings, strategy and business development activities. In 2001 he led the Company's initial public offering on the AIM stock exchange in London, and in 2013 led the Company's initial public offering in the U.S. on Nasdaq. In total, he has led equity financings which have raised over $1 billion for the Company. In 2015 Mr. Gover relocated to the U.S. to open the Company's U.S. headquarters in California.Prior to joining the Company, Mr. Gover was Head of Corporate Affairs at Amarin, where he was responsible for the company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations. Mr. Gover serves on the board of directors of the Biotechnology Innovation Organization. He holds an M.B.A. from the INSEAD business school in France and a BSc Hons from Bristol University. - 1999年1月以来，Justin Gover担任首席执行官。他拥有17年制药行业的经验。作为一名首席执行官，他负责业务运行以及领先的股本融资和商业开发活动。从1995年到1997年，他担任道德控股有限公司负责人，他负责战略活动，包括并购、战略投资、股权融资和投资者关系。他拥有欧洲工商管理学院硕士学位和布里斯托尔大学的理学学士学位。
- Justin Gover has served as Chief Executive Officer of the Company since January 1999 shortly after the Company was founded.As Chief Executive Officer, Mr. Gover has been the lead executive responsible for running the Company's operations, as well as leading equity financings, strategy and business development activities. In 2001 he led the Company's initial public offering on the AIM stock exchange in London, and in 2013 led the Company's initial public offering in the U.S. on Nasdaq. In total, he has led equity financings which have raised over $1 billion for the Company. In 2015 Mr. Gover relocated to the U.S. to open the Company's U.S. headquarters in California.Prior to joining the Company, Mr. Gover was Head of Corporate Affairs at Amarin, where he was responsible for the company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations. Mr. Gover serves on the board of directors of the Biotechnology Innovation Organization. He holds an M.B.A. from the INSEAD business school in France and a BSc Hons from Bristol University.
高管简历
中英对照 | 中文 | 英文- Christopher Kenney
Christopher Kenney，受雇于Xenon制药全资子公司Xenon Pharmaceuticals Inc. USA Inc.，自2021年8月起担任TERM3首席医疗官。肯尼博士是一位获得董事会认证的神经学家，在神经科学领域拥有超过20年的行业和学术角色的丰富临床研究经验。最近，肯尼博士在Cadent Therapeutics担任首席医疗官，该公司是一家生物技术公司，专注于为神经和精神疾病创造突破性疗法，从2019年到2021年5月被诺华收购。此前，Kenney博士曾于2018-2019年担任医疗事务高级副总裁，并于2016年至2018年担任临床开发高级副总裁，任职于阿索尔达治疗，这是一家专注于开发帕金森病、偏头痛和多发性硬化症的神经内科疗法并将其商业化的生物技术公司。在担任该职位之前，2013年至2016年，Kenney博士在Biotie Therapies担任临床开发副总裁/高级副总裁，该公司是一家专注于神经退行性疾病和精神疾病的生物技术公司，于2016年1月被阿索尔达治疗收购。在加入Biotie之前，Kenney博士曾在诺华和默沙东 Serono从事临床开发工作。肯尼博士的核心医学和神经病学培训在波士顿大学医学院和加州大学圣地亚哥分校（UCSD）进行。肯尼博士曾于2005年至2007年在贝勒大学担任教职，并于2003年至2005年在加州大学圣地亚哥分校担任教职。2020年，肯尼博士被任命为美国神经病学研究院院士。
Christopher Kenney,is employed by Xenon Pharmaceuticals Inc. wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., and has served as Xenon Pharmaceuticals Inc. Chief Medical Officer since August 2021. Dr. Kenney is a board-certified neurologist with extensive clinical research experience within neuroscience in both industry and academic roles spanning more than 20 years. Most recently, Dr. Kenney served as Chief Medical Officer at Cadent Therapeutics, a biotech company focused on creating breakthrough therapies for neurological and psychiatric conditions, from 2019 until May 2021 when it was acquired by Novartis. Previously, Dr. Kenney was Senior Vice President of Medical Affairs, from 2018-2019, and Senior Vice President, Clinical Development, from 2016 to 2018, at Acorda Therapeutics, a biotechnology company focused on developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Prior to that position, from 2013 to 2016, Dr. Kenney served as Vice President/Senior Vice President of Clinical Development at Biotie Therapies, a biotechnology company focused on neurodegenerative and psychiatric disorders that was acquired by Acorda Therapeutics in January 2016. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. Dr. Kenney's core medical and neurology training took place at Boston University School of Medicine and at University of California, San Diego (UCSD). Dr. Kenney held faculty positions at Baylor University, from 2005 to 2007, and the University of California, San Diego, from 2003 to 2005. In 2020, Dr. Kenney was appointed as a Fellow of the American Academy of Neurology.- Christopher Kenney，受雇于Xenon制药全资子公司Xenon Pharmaceuticals Inc. USA Inc.，自2021年8月起担任TERM3首席医疗官。肯尼博士是一位获得董事会认证的神经学家，在神经科学领域拥有超过20年的行业和学术角色的丰富临床研究经验。最近，肯尼博士在Cadent Therapeutics担任首席医疗官，该公司是一家生物技术公司，专注于为神经和精神疾病创造突破性疗法，从2019年到2021年5月被诺华收购。此前，Kenney博士曾于2018-2019年担任医疗事务高级副总裁，并于2016年至2018年担任临床开发高级副总裁，任职于阿索尔达治疗，这是一家专注于开发帕金森病、偏头痛和多发性硬化症的神经内科疗法并将其商业化的生物技术公司。在担任该职位之前，2013年至2016年，Kenney博士在Biotie Therapies担任临床开发副总裁/高级副总裁，该公司是一家专注于神经退行性疾病和精神疾病的生物技术公司，于2016年1月被阿索尔达治疗收购。在加入Biotie之前，Kenney博士曾在诺华和默沙东 Serono从事临床开发工作。肯尼博士的核心医学和神经病学培训在波士顿大学医学院和加州大学圣地亚哥分校（UCSD）进行。肯尼博士曾于2005年至2007年在贝勒大学担任教职，并于2003年至2005年在加州大学圣地亚哥分校担任教职。2020年，肯尼博士被任命为美国神经病学研究院院士。
- Christopher Kenney,is employed by Xenon Pharmaceuticals Inc. wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., and has served as Xenon Pharmaceuticals Inc. Chief Medical Officer since August 2021. Dr. Kenney is a board-certified neurologist with extensive clinical research experience within neuroscience in both industry and academic roles spanning more than 20 years. Most recently, Dr. Kenney served as Chief Medical Officer at Cadent Therapeutics, a biotech company focused on creating breakthrough therapies for neurological and psychiatric conditions, from 2019 until May 2021 when it was acquired by Novartis. Previously, Dr. Kenney was Senior Vice President of Medical Affairs, from 2018-2019, and Senior Vice President, Clinical Development, from 2016 to 2018, at Acorda Therapeutics, a biotechnology company focused on developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Prior to that position, from 2013 to 2016, Dr. Kenney served as Vice President/Senior Vice President of Clinical Development at Biotie Therapies, a biotechnology company focused on neurodegenerative and psychiatric disorders that was acquired by Acorda Therapeutics in January 2016. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. Dr. Kenney's core medical and neurology training took place at Boston University School of Medicine and at University of California, San Diego (UCSD). Dr. Kenney held faculty positions at Baylor University, from 2005 to 2007, and the University of California, San Diego, from 2003 to 2005. In 2020, Dr. Kenney was appointed as a Fellow of the American Academy of Neurology.
- Andrea DiFabio
Andrea DiFabio受雇于Xenon制药公司全资子公司Xenon Pharmaceuticals Inc. USA Inc.，自2022年11月起担任TERM3首席法务官和公司秘书。在加入Xenon Pharmaceuticals Inc.之前，DiFabio女士于2020年3月至2022年10月担任Repertoire Immune Medicines，Inc.的首席法律与行政官兼公司秘书，在那里她积累了支持公司各个方面的广泛经验，包括业务和临床开发、投资者沟通、风险管理以及开发公司的知识产权和沟通战略。2019年2月至2020年3月，DiFabio女士在Codiak BioSciences, Inc.担任首席法务官和公司秘书。在2018年初被赛诺菲以116亿美元收购之前，DiFabio女士曾在Bioverativ Inc.担任执行副总裁、首席法务官和公司秘书，此前她在Biogen Inc.的这家衍生公司中发挥了关键作用。此前，DiFabio女士于2006年加入渤健，担任公司法律顾问，随后于2007年晋升为副总裁兼首席美国法律顾问；副总裁，2009年担任首席研发顾问；2014年担任高级副总裁、首席研究和业务发展顾问；2016年担任Bioverativ（作为渤健的子公司）首席法务官，在这些职位上，她参与了关键的战略交易，以及众多神经病学产品的批准和推出。在任职于渤健之前，从1999年到2006年，DiFabio女士是公开上市的临床研究机构Parexel International的执行团队成员和高级法律顾问。DiFabio女士在东北大学法学院获得法学博士学位，并在波士顿大学以优异成绩获得文学学士学位。
Andrea DiFabio,is employed by Xenon Pharmaceuticals Inc. wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., and has served as Xenon Pharmaceuticals Inc. Chief Legal Officer and Corporate Secretary since November 2022. Prior to joining Xenon Pharmaceuticals Inc. , Ms. DiFabio was the Chief Legal & Administrative Officer and Corporate Secretary at Repertoire Immune Medicines, Inc. from March 2020 to October 2022, where she developed broad experience supporting all aspects of the company, including business and clinical development, investor communications, risk management, and developing the company's IP and communication strategy. From February 2019 to March 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc. Prior to its acquisition by Sanofi for $11.6 billion in early 2018, Ms. DiFabio served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Bioverativ Inc. from September 2016 to June 2018 after playing a key role in this spinoff company of Biogen Inc. Previously, Ms. DiFabio joined Biogen in 2006 as Corporate Counsel and was subsequently promoted to Vice President, Chief US Counsel in 2007; Vice President, Chief Research and Development Counsel in 2009; Senior Vice President, Chief Research and Business Development Counsel in 2014; and Chief Legal Officer, Bioverativ (as a subsidiary of Biogen) in 2016, in which positions she was involved in key strategic transactions, as well as the approval and launch of numerous neurology products. Prior to her experience at Biogen, from 1999 to 2006, Ms. DiFabio was a member of the executive team and senior legal counsel at Parexel International, a publicly traded clinical research organization. Ms. DiFabio earned a Juris Doctor degree from Northeastern University School of Law, and a Bachelor of Arts, Summa Cum Laude from Boston University.- Andrea DiFabio受雇于Xenon制药公司全资子公司Xenon Pharmaceuticals Inc. USA Inc.，自2022年11月起担任TERM3首席法务官和公司秘书。在加入Xenon Pharmaceuticals Inc.之前，DiFabio女士于2020年3月至2022年10月担任Repertoire Immune Medicines，Inc.的首席法律与行政官兼公司秘书，在那里她积累了支持公司各个方面的广泛经验，包括业务和临床开发、投资者沟通、风险管理以及开发公司的知识产权和沟通战略。2019年2月至2020年3月，DiFabio女士在Codiak BioSciences, Inc.担任首席法务官和公司秘书。在2018年初被赛诺菲以116亿美元收购之前，DiFabio女士曾在Bioverativ Inc.担任执行副总裁、首席法务官和公司秘书，此前她在Biogen Inc.的这家衍生公司中发挥了关键作用。此前，DiFabio女士于2006年加入渤健，担任公司法律顾问，随后于2007年晋升为副总裁兼首席美国法律顾问；副总裁，2009年担任首席研发顾问；2014年担任高级副总裁、首席研究和业务发展顾问；2016年担任Bioverativ（作为渤健的子公司）首席法务官，在这些职位上，她参与了关键的战略交易，以及众多神经病学产品的批准和推出。在任职于渤健之前，从1999年到2006年，DiFabio女士是公开上市的临床研究机构Parexel International的执行团队成员和高级法律顾问。DiFabio女士在东北大学法学院获得法学博士学位，并在波士顿大学以优异成绩获得文学学士学位。
- Andrea DiFabio,is employed by Xenon Pharmaceuticals Inc. wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., and has served as Xenon Pharmaceuticals Inc. Chief Legal Officer and Corporate Secretary since November 2022. Prior to joining Xenon Pharmaceuticals Inc. , Ms. DiFabio was the Chief Legal & Administrative Officer and Corporate Secretary at Repertoire Immune Medicines, Inc. from March 2020 to October 2022, where she developed broad experience supporting all aspects of the company, including business and clinical development, investor communications, risk management, and developing the company's IP and communication strategy. From February 2019 to March 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc. Prior to its acquisition by Sanofi for $11.6 billion in early 2018, Ms. DiFabio served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Bioverativ Inc. from September 2016 to June 2018 after playing a key role in this spinoff company of Biogen Inc. Previously, Ms. DiFabio joined Biogen in 2006 as Corporate Counsel and was subsequently promoted to Vice President, Chief US Counsel in 2007; Vice President, Chief Research and Development Counsel in 2009; Senior Vice President, Chief Research and Business Development Counsel in 2014; and Chief Legal Officer, Bioverativ (as a subsidiary of Biogen) in 2016, in which positions she was involved in key strategic transactions, as well as the approval and launch of numerous neurology products. Prior to her experience at Biogen, from 1999 to 2006, Ms. DiFabio was a member of the executive team and senior legal counsel at Parexel International, a publicly traded clinical research organization. Ms. DiFabio earned a Juris Doctor degree from Northeastern University School of Law, and a Bachelor of Arts, Summa Cum Laude from Boston University.
- Thomas Kelly
Thomas Kelly，此前于2019年1月至2024年6月被小野制药收购之前担任首席财务官和财务主管的Deciphera执行副总裁、首席财务官和TERM3。自2015年2月起担任财务主管。在加入Deciphera之前，Kelly先生曾在多家公共和私营生命科学公司担任首席财务官，包括AdvanDx，Inc.、deCODEGenetics，Inc.和Critical Therapeutics，Inc.。在担任这些职务之前，Kelly先生是Robertson Stephens和Canaccord Adams的生命科学投资银行家，职业生涯早期是Foley Hoag LLP公司和证券集团的律师。凯利先生以优异成绩获得了芝加哥大学法学院的法学博士学位和乔治城大学外交服务学院的外交服务学士学位。
Thomas Kelly,previously served as Executive Vice President, Chief Financial Officer and Treasurer of Deciphera Pharmaceuticals, Inc. from January 2019 until its acquisition by Ono Pharmaceutical Co., Ltd. in June 2024, and as Deciphera's Chief Financial Officer and Treasurer since February 2015. Before joining Deciphera, Mr. Kelly served as Chief Financial Officer of various public and private life sciences companies including AdvanDx, Inc., deCODE genetics, Inc., and Critical Therapeutics, Inc. Prior to these roles, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams, and earlier in his career was an attorney in the corporate and securities group of Foley Hoag LLP. Mr. Kelly earned a J.D. with honors from the University of Chicago Law School and a B.S. in Foreign Service, cum laude, from the Georgetown University School of Foreign Service.- Thomas Kelly，此前于2019年1月至2024年6月被小野制药收购之前担任首席财务官和财务主管的Deciphera执行副总裁、首席财务官和TERM3。自2015年2月起担任财务主管。在加入Deciphera之前，Kelly先生曾在多家公共和私营生命科学公司担任首席财务官，包括AdvanDx，Inc.、deCODEGenetics，Inc.和Critical Therapeutics，Inc.。在担任这些职务之前，Kelly先生是Robertson Stephens和Canaccord Adams的生命科学投资银行家，职业生涯早期是Foley Hoag LLP公司和证券集团的律师。凯利先生以优异成绩获得了芝加哥大学法学院的法学博士学位和乔治城大学外交服务学院的外交服务学士学位。
- Thomas Kelly,previously served as Executive Vice President, Chief Financial Officer and Treasurer of Deciphera Pharmaceuticals, Inc. from January 2019 until its acquisition by Ono Pharmaceutical Co., Ltd. in June 2024, and as Deciphera's Chief Financial Officer and Treasurer since February 2015. Before joining Deciphera, Mr. Kelly served as Chief Financial Officer of various public and private life sciences companies including AdvanDx, Inc., deCODE genetics, Inc., and Critical Therapeutics, Inc. Prior to these roles, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams, and earlier in his career was an attorney in the corporate and securities group of Foley Hoag LLP. Mr. Kelly earned a J.D. with honors from the University of Chicago Law School and a B.S. in Foreign Service, cum laude, from the Georgetown University School of Foreign Service.
- Ian C. Mortimer
Ian C. Mortimer，他是工商管理硕士、注册会计师、美国注册管理会计师 。他曾一直担任首席财务官（2013年10月以来）。加入之前，他曾担任Tekmira Pharmaceuticals Corporation（Tekmira，纳斯达克上市的生物技术公司，专注于RNA干扰的发展、RNAi、治疗药物）的执行副总裁兼首席财务官。他负责Tekmira公司的财务和资本市场活动的所有方面，并于2010年领导Tekmira公司在纳斯达克的上市。从2004年到2007年，他曾担任Inex Pharmaceuticals公司的首席财务官，也曾担任Inex Pharmaceuticals公司的多种其它职务（从1997年到2004年）。他持有Queen大学的工商管理硕士学位，以及British Columbia大学的微生物学学士学位。他是特许专业会计师、注册管理会计师。
Ian C. Mortimer, M.B.A., CPA, CMA has served as President and Chief Financial Officer since March 2018 and additionally as Corporate Secretary since June 2015. Mr. Mortimer previously served as Chief Financial Officer and Chief Operating Officer since March 2015 and as Chief Financial Officer since October 2013. Prior to joining, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation "Tekmira" (now Arbutus Biopharma Corporation), a NASDAQ-listed biotechnology company, from 2007 until October 2013. Mr. Mortimer was responsible for all aspects of Tekmira's finance and capital markets activities and led Tekmira's listing on NASDAQ in 2010. From 2004 to 2007 Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Since November 2017 Mr. Mortimer has served on the Board of Directors and as Chair of the Audit Committee for Appili Therapeutics, a private biopharmaceutical company focused on developing treatments for infectious diseases. Mr. Mortimer has an M.B.A. from Queen's University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.- Ian C. Mortimer，他是工商管理硕士、注册会计师、美国注册管理会计师 。他曾一直担任首席财务官（2013年10月以来）。加入之前，他曾担任Tekmira Pharmaceuticals Corporation（Tekmira，纳斯达克上市的生物技术公司，专注于RNA干扰的发展、RNAi、治疗药物）的执行副总裁兼首席财务官。他负责Tekmira公司的财务和资本市场活动的所有方面，并于2010年领导Tekmira公司在纳斯达克的上市。从2004年到2007年，他曾担任Inex Pharmaceuticals公司的首席财务官，也曾担任Inex Pharmaceuticals公司的多种其它职务（从1997年到2004年）。他持有Queen大学的工商管理硕士学位，以及British Columbia大学的微生物学学士学位。他是特许专业会计师、注册管理会计师。
- Ian C. Mortimer, M.B.A., CPA, CMA has served as President and Chief Financial Officer since March 2018 and additionally as Corporate Secretary since June 2015. Mr. Mortimer previously served as Chief Financial Officer and Chief Operating Officer since March 2015 and as Chief Financial Officer since October 2013. Prior to joining, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation "Tekmira" (now Arbutus Biopharma Corporation), a NASDAQ-listed biotechnology company, from 2007 until October 2013. Mr. Mortimer was responsible for all aspects of Tekmira's finance and capital markets activities and led Tekmira's listing on NASDAQ in 2010. From 2004 to 2007 Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Since November 2017 Mr. Mortimer has served on the Board of Directors and as Chair of the Audit Committee for Appili Therapeutics, a private biopharmaceutical company focused on developing treatments for infectious diseases. Mr. Mortimer has an M.B.A. from Queen's University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.